Evidence map›Paper›PMID 42449914›Full record

ReviewDiagnostics (Basel, Switzerland)2026

Current Landscape of Molecular Diagnostic Tests and Emerging Tools for Tuberculosis and Drug Resistance.

Safaa El Kassimi, Rkia Eddabra, Bouchra Belkadi, Abdelkarim Filali-Maltouf, Hassan Ait Benhassou

Abstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Safaa El KassimiLaboratory of Microbiology and Molecular Biology, Faculty of Sciences of Rabat, Mohammed V University, Rabat 10100, Morocco.
Rkia EddabraHigher Institute of Nursing Professions and Technical Health, Agadir 80000, Morocco.ORCID 0000-0002-0365-9391
Bouchra BelkadiLaboratory of Microbiology and Molecular Biology, Faculty of Sciences of Rabat, Mohammed V University, Rabat 10100, Morocco.
Abdelkarim Filali-MaltoufLaboratory of Microbiology and Molecular Biology, Faculty of Sciences of Rabat, Mohammed V University, Rabat 10100, Morocco.ORCID 0000-0002-2727-3389
Hassan Ait BenhassouPrevention & Therapeutics Center, Moroccan Foundation for Advanced Science, Innovation and Research (MAScIR), Mohammed VI Polytechnic University (UM6P), Ben Guerir 43150, Morocco.ORCID 0000-0002-5815-3531

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review synthesizes recent advances in WHO-endorsed NAATs for TB diagnosis and drug resistance detection. We examine the principles, genetic targets, diagnostic performance, implementation settings, and programmatic role of assays across the spectrum of technological complexity, from cartridge-based platforms to line probe assays and sequencing-based technologies. In addition, we highlight emerging molecular tools that show promise for future WHO endorsement and may further strengthen decentralized and near-patient testing. Low- and moderate-complexity assays such as Xpert

Indexed as

molecular diagnosticsMycobacterium tuberculosisnucleic acid amplification tests (NAATS)Tuberculosis (TB)

Identifiers

PMID42449914
PMCPMC13361649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.